Development-stage Biolink promotes dialysis access device as likely to make substantial savings
This article was originally published in Clinica
Biolink, a five-year old US development-stage company, is attempting to remove the problems associated with vessel exhaustion in haemodialysis. Its device looks likely to reduce patient costs, cut down hospitalisation and even prevent infection-related deaths, by adapting concepts from oncology practice.
You may also be interested in...
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.